AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06753773 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repeated Low-Level Red-Light
Description: All participants will receive a video guide of the Repeated Low-Level Red-Light device. Eligible subjects will receive daily treatment for 14 days, with each treatment lasting for 3 minutes twice a day, with a minimal interval of 4 hours.
Study NCT06754891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH3906 capsules
Description: TQH3906 is an allosteric inhibitor targeting kinase.
Study NCT06753214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine-Based Education
Description: Intervention through telemedicine
Study NCT06753214 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Care (in control arm)
Description: Sham comparator through telemedicine
Study NCT06755203 — intervention group
Intervention type: OTHER
Intervention: Operating Room Simulation Training
Description: The intervention involves high-fidelity OR simulations focusing on critical areas of patient safety, including:~Communication Skills: Emphasizing clear communication during surgical procedures.~Stress Management: Training participants to manage stress effectively in high-pressure situations.~Protocol Adherence: Practicing adherence to the WHO Surgical Safety Checklist. Risk Assessment: Identifying and mitigating potential safety risks in simulated scenarios
Study NCT05281419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone injection
Description: Injecting 40mg triamcinolone into the abscess cavity through the aspiration needle or drainage tube every 1 week
Study NCT05281419 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intralesional triamcinolone injection
Description: No intralesional triamcinolone injection
Study NCT04653571 — intervention group
Intervention type: OTHER
Intervention: CASPR2 encephalitis
Description: Defining the initial clinical symptoms and those leading to the diagnosis of CASPR2 antibody associated encephalitis. For that, we will investigate the initial cognitive status, the initial neuropsychological investigations the clinical presentation of the first seizures, and the prodromes assessed by patients at the beginning of their disease. We will also look at the initial EEG records, in order to acknowledge whether the initial cognitive symptoms may be due to unseen seizures.
Study NCT05732337 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Poxclin Coolmousse
Description: cooling mousse for application in the skin
Study NCT05684861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: systemic isotretinoin was given to all 90 patients , dose was prescribed according to weight for 3 months
Study NCT05684861 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ELISA Assays of Serum TWEAK.
Description: : From each subject, 5mL of blood was collected into vacutainers before and after treatment with isotretinoin. The blood samples were centrifuged at 3000g for 10 min at a temperature of 4°C, then . Quantitative determinations for serum TWEAK were achieved using the corresponding commercially available ELISA kit supplied by the AssayMax
Study NCT05999071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coriandrum sativum seeds
Description: Each group consisted of 50 students. In the C. sativum group, dried powdered seeds of C. sativum were administered, while in the control group, starch was provided as a placebo. Both the C. sativum and placebo capsules were identical in shape, color, and outer packaging to maintain the blinding of the participants.
Study NCT05999071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Coriandrum sativum seeds
Description: Each group consisted of 50 students. In the C. sativum group, dried powdered seeds of C. sativum were administered, while in the control group, starch was provided as a placebo. Both the C. sativum and placebo capsules were identical in shape, color, and outer packaging to maintain the blinding of the participants.
Study NCT04495972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intestinimonas-capsules
Description: Capsules containing microbiota (Intestinimonas)
Study NCT04495972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-capsules
Description: Placebo capsules are identical to the active treatment
Study NCT05571475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated competition
Description: During a competition, athletes will typically compete for a reward, against opponents and in the presence of others. This will be replicated in the laboratory.
Study NCT06322641 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study NCT05691582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GRAIL
Description: The subjects experiment GRAIL virtual reality for three days, during which they deal with 4 different activities.~In the first activity subjects are required to ask over the treadmill in a snow environment.~in the second they are required to stand over the moving platform in a simulation of a boat pitch.~in the third they have to walk over a bridge with a slope. in the fourth the subjects are required to try so interact with virtual reality and to ski between snowman.~if it is possible, on the last day a gait analysis is executed
Study NCT03533153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WJ-MSC cells implantation
Description: Laboratory of Stem Cell of Drum Tower Hospital, Nanjing University Medical School, is able to provide types of Good Manufacture Practice (GMP) level stem cells and stem cell-based medicinal products. Clinical-grade WJ-MSC primary cells are cultured to 4\~ 8 passages, and the surface markers (CD90+, CD105+, CD45-, CD31-, CD117-) are identified by flow cytometry. WJ-MSC cells are trypsinized and resuspended in the wash buffer of CTSTMD PBS (+Ca2+, +Mg2+). Within 2 hours after enzyme digestion, WJ-MSC cells are shipped to coronary care unit (CCU) and injected into the body.
Study NCT03533153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CTSTMD PBS without WJ-MSC
Description: For Case-control study only.
Study NCT03533153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional drug therapy
Description: All patients undergo guideline-recommended treatment for STEMI, including aspirin (loading dose of 300mg before maintenance dose of 100 mg/d), clopidogrel (loading dose of 300mg before maintenance dose of 75 mg/d) or Ticagrelor (loading dose of 300mg before maintenance dose of 90 mg/d), angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), β-receptor blockers, statins and nitrate esters.
Study NCT03533153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional drug therapy
Description: All patients undergo guideline-recommended treatment for STEMI, including aspirin (loading dose of 300mg before maintenance dose of 100 mg/d), clopidogrel (loading dose of 300mg before maintenance dose of 75 mg/d) or Ticagrelor (loading dose of 300mg before maintenance dose of 90 mg/d), angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), β-receptor blockers, statins and nitrate esters.
Study NCT04674813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-95266
Description: Specified dose on specified days
Study NCT04674813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days
Study NCT04674813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days
Study NCT04674813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Specified dose on specified days
Study NCT04828018 — intervention group
Intervention type: OTHER
Intervention: Coffee Morning
Description: Coffee mornings (a maximum of n=2) will be held to raise awareness of the project and to promote participant recruitment. These will be held remotely via video conference if Covid-19 restrictions prevent in-person attendance by the researcher.
Study NCT04828018 — intervention group
Intervention type: OTHER
Intervention: Recruitment Leaflets
Description: Recruitment leaflets will be hand-delivered to all In-Pensioner residents at Royal Hospital Chelsea. Leaflets will be delivered internally by Royal Hospital Chelsea internal mail-room
Study NCT04398355 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture
Study NCT04398355 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Liu-Zi-Jue Gongfa
Description: Liu-Zi-Jue Gongfa
Study NCT04872842 — intervention group
Intervention type: OTHER
Intervention: Obervation
Description: This study is an observational study without any intervention
Study NCT04913064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04913064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: White Button Mushroom Extract
Description: Given PO
Study NCT06513338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: eculizumab 900mg iv. per week for 4 weeks, then 1200mg every two weeks for week 5 to. week 11
Study NCT06026527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: 50 mg/kg Magnesium sulphate in 93-95 ml Normal Saline ( making a total of 100 ml solution )will be infused intravenously over 20-30 minutes in the participants allocated to M group starting from the moment of induction of anaesthesia
Study NCT06026527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 100 ml Normal Saline will be infused intravenously over 20-30 minutes in the participants allocated to control group starting from the moment of induction of anaesthesia
Study NCT05483348 — intervention group
Intervention type: PROCEDURE
Intervention: Endometrial Ablation
Description: Thermal endometrial ablation
Study NCT04828018 — intervention group
Intervention type: OTHER
Intervention: Consent Form completion
Description: All participants will be asked to complete Consent Forms before engaging in the study. The researcher will be available to answer any questions via phone calls if required.
Study NCT05483348 — intervention group
Intervention type: PROCEDURE
Intervention: Repeated gynecological procedure
Description: subsequent gynecological procedures such as hysterectomy for any benign indication, D\&C or repeat ablation.
Study NCT04935502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home based exercises with postural and ergonomic training
Description: Group A will be treated with stretching and strenghtening exercises for 40 minutes along with postural and ergonomic training for 15 minutes session 3 days/week for 4 week.
Study NCT04935502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home based exercises
Description: Group B will be given stretching and strengthening exercises for 40 minutes, every alternate day (3 days per week) for 4 weeks.
Study NCT04828018 — intervention group
Intervention type: OTHER
Intervention: Participant Information Sheet
Description: All participants will receive Information Sheets which they will read in their own rooms (or elsewhere for Key Staff). The researcher will be available to answer any questions via phone calls if required.
Study NCT04828018 — intervention group
Intervention type: OTHER
Intervention: New In-Pensioner Resident Information Pack
Description: New In-Pensioner resident information packs will be distributed by a member of RHC staff as part of their 'arrivals' process and six months after residency at RHC. The researcher will be available to answer any questions via phone calls if required.
Study NCT05924152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adagrasib
Description: Adagrasib
Study NCT05924152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag + adagrasib
Description: Eltrombopag + adagrasib
Study NCT06034860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8421
Description: Experimental treatment with MT-8421
Study NCT06034860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg nivolumab administered on Day 1 of each cycle starting with Cycle 2 for all combination dose escalation and dose expansion cohorts
Study NCT06200181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Given by PO
Study NCT06200181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given by PO
Study NCT05289167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg IV over 1 hour on Day +3 and +4
Study NCT05289167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Dose level 0: 10 mg/kg IV over 30 minutes on day +5~Dose level 1: 10mg/kg IV over 30 minutes on day +5 and +14~Dose level 2: 10mg/kg IV over 30 minutes on day +5, +14, and +28
Study NCT05289167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2 IV 6 hours after graft infusion completion and 72 hours thereafter.
Study NCT05463328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic assisted pancreaticoduodenectomy
Description: laparoscopic assisted pancreaticoduodenectomy.
Study NCT05463328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open pancreaticduodenctomy
Description: Open pancreaticduodenctomy
Study NCT06371833 — intervention group
Intervention type: DEVICE
Intervention: Shoulder Arthroplasy with PRIMA humeral stem
Description: Data collection of population that underwent a total shoulder arthroplasty with PRIMA humeral stem (anatomic configuration or reverse configuration)
Study NCT04828018 — intervention group
Intervention type: OTHER
Intervention: Key Staff Interviews
Description: Key Staff interviews will take place with the Researcher in a private space at Royal Hospital Chelsea. If Covid-19 restrictions are in place, 'online' interviews will take place using a digital platform such as 'Skype', 'Teams' or 'Zoom'.
Study NCT06241404 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trigger point therapy
Description: patients who have been treated for shoulder tendinopathy by trigger point therapy
Study NCT06241404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: patients who have been treated for shoulder tendinopathy by exercise therapy
Study NCT05558033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric Exercise
Description: Plyometric training consisting of ten different exercises \[vertical unilateral and bilateral counter movement jump, horizontal unilateral and bilateral counter movement jump, drop jump (30 cm), squat jump, step-hop (20 cm), 180 degree rotation in transverse plane, frontal plane hurdle jump (20 cm) and sagittal plane hurdle jump (20 cm)\] for 8 weeks, 3 sessions per week. Individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery)
Study NCT05558033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Football Training
Description: Routine football trainings
Study NCT04828018 — intervention group
Intervention type: OTHER
Intervention: In-Pensioner Resident Interviews
Description: In-Pensioner resident interviews will take place with the Researcher in a private space at Royal Hospital Chelsea. If Covid-19 restrictions are in place, 'online' interviews will take place using a digital platform such as 'Skype', 'Teams' or 'Zoom'.
Study NCT05119920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Ophthalmic Topical Cream, Dose 1
Description: Pilocarpine Ophthalmic Topical Cream, Dose 1
Study NCT05119920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Ophthalmic Topical Cream, Dose 2
Description: Pilocarpine Ophthalmic Topical Cream, Dose 2
Study NCT05119920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Ophthalmic Topical Cream, Dose 3
Description: Pilocarpine Ophthalmic Topical Cream, Dose 3
Study NCT05119920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Topical Cream
Description: Placebo Ophthalmic Topical Cream
Study NCT06285682 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OliPhenolia®)
Description: Olive derived hydroxytyrosol will be ingested via a commercially available olive fruit wastewater (OliPhenolia®) in a dose relative to participant body mass. Participants will consume three doses within the entire study, one dose per visit, separated by a ≥3 day wash out period.
Study NCT05880095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unrestricted Mediterranean diet
Description: Participants will received nutritional educational information to encourage their adherence to a Mediterranean dietary pattern. Neither caloric restriction nor time-eating restriction will be indicated.
Study NCT05880095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy-reduced Mediterranean diet
Description: Participants will follow a Mediterranean diet with a 25% caloric restriction. Participants will be provided with dietary programs, menus, shopping lists and other educational material to encourage adherence to the intervention.
Study NCT05880095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with time-restricted eating
Description: Participants will follow the same dietary guidelines given to MedD group, but they must to adjust their daily meals to a self-selected 10-hour eating window. This 10h eating window of their choice should be comprised between 6.00 to 20.00h. Participants will be allowed to consume water and non-caloric drinks during the fasting period (outside the 10h eating window). Participants will be advised to follow the 10h TRE during weekdays and weekends.
Study NCT04828018 — intervention group
Intervention type: OTHER
Intervention: ICECAP-A Quality of Life Questionnaire
Description: New In-Pensioner residents and In-Pensioner residents taking part in the Qualitative Interviews will be asked to complete n=2 QoL questionnaires. New In-Pensioners will be asked to complete their QoL measures when the individual takes up residence at Royal Hospital Chelsea, the second six months later. In-Pensioner residents taking part in the interviews will be asked to complete the questionnaire at the start of the interview.
Study NCT04828018 — intervention group
Intervention type: OTHER
Intervention: WHOQOL-BREF Quality of Life Questionnaire
Description: New In-Pensioner residents and In-Pensioner residents taking part in the Qualitative Interviews will be asked to complete n=2 QoL questionnaires. New In-Pensioners will be asked to complete their QoL measures when the individual takes up residence at Royal Hospital Chelsea, the second six months later. In-Pensioner residents taking part in the interviews will be asked to complete the questionnaire at the start of the interview.
Study NCT05244473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Given into the vein (IV; intravenously)
Study NCT05244473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given by IV
Study NCT05244473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART
Description: Daily use of a combination of HIV medicines
Study NCT05244473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ART
Description: Daily use of a combination of HIV medicines
Study NCT04050189 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Natural products: Probiotics
Description: Probiotics intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum
Study NCT03495479 — intervention group
Intervention type: DRUG
Intervention: OMN54
Description: Twice daily, self administered, oral dosing of OMN54. A daily diary log will be prepared by each participant and reviewed by the Investigator.
Study NCT04050189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum
Study NCT06422052 — intervention group
Intervention type: OTHER
Intervention: Epidemiological questionnaire and Functional Dyspepsia Symptom Diary（FDSD）
Description: H. pylori infection was confirmed by 13C/ 14C-breath test and/or rapid urease test under endoscopy and histopathological examination. Epidemiological questionnaire and Functional Dyspepsia Symptom Diary (FDSD) were used to investigate basic information and assess dyspeptic symptoms. Patients with dyspepsia who successfully eradicated Helicobacter pylori infection will be followed up for dyspeptic symptoms after 2 months and 6 months to evaluate the relief of dyspeptic symptoms.
Study NCT05636358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based hypnotherapy
Description: The home-based hypnotherapy package contains five standard hypnosis exercises. They consist of one breathing exercise, and four visualisation exercises. Two separate sets adjusted to the child's age will be used: one for children younger than 12 years and one for children of 12 years and older. The children will be asked to listen to the exercises at least 5 times per week, for approximately 15-20 minutes per day, during a period of 3 months. A workbook will provide children and/or parents with the instructions and planning of the exercises.
Study NCT05067478 — intervention group
Intervention type: DRUG
Intervention: Vibegron
Description: Vibegron to be administered.
Study NCT06128681 — intervention group
Intervention type: PROCEDURE
Intervention: Intraairway ultrasound-guided mediastinal opening technique
Description: Mediastinal intervention for patients with mediastinal imaging abnormalities is performed under general anesthesia to obtain biopsy specimens for detection or elimination of mediastinal masses